Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses.

Markowitz LE, Naleway AL, Klein NP, Lewis RM, Crane B, Querec TD, Hsiao A, Aukes L, Timbol J, Weinmann S, Liu G, Steinau M, Unger ER.

J Infect Dis. 2019 Nov 30. pii: jiz555. doi: 10.1093/infdis/jiz555. [Epub ahead of print]

PMID:
31784749
2.

Chorioamnionitis: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.

Kachikis A, Eckert LO, Walker C, Bardají A, Varricchio F, Lipkind HS, Diouf K, Huang WT, Mataya R, Bittaye M, Cutland C, Boghossian NS, Mallett Moore T, McCall R, King J, Mundle S, Munoz FM, Rouse C, Gravett M, Katikaneni L, Ault K, Klein NP, Roberts DJ, Kochhar S, Chescheir N; Brighton Collaboration Chorioamnionitis Working Group.

Vaccine. 2019 Dec 10;37(52):7610-7622. doi: 10.1016/j.vaccine.2019.05.030. No abstract available.

3.

Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine.

Donahue JG, Kieke BA, Lewis EM, Weintraub ES, Hanson KE, McClure DL, Vickers ER, Gee J, Daley MF, DeStefano F, Hechter RC, Jackson LA, Klein NP, Naleway AL, Nelson JC, Belongia EA.

Pediatrics. 2019 Dec;144(6). pii: e20191808. doi: 10.1542/peds.2019-1808. Epub 2019 Nov 18.

PMID:
31740498
4.

Assessment of Exemptions From Vaccination in California, 2015 to 2027.

Delamater PL, Buttenheim AM, Klein NP, Mohanty S, Salmon DA, Omer SB.

Ann Intern Med. 2019 Nov 5. doi: 10.7326/M19-1933. [Epub ahead of print] No abstract available.

PMID:
31683313
5.

Parental risk factors for fever in their children 7-10 days after the first dose of measles-containing vaccines.

Zerbo O, Modaressi S, Goddard K, Lewis E, Bok K, Gans H, Klein NP.

Hum Vaccin Immunother. 2019 Nov 8:1-6. doi: 10.1080/21645515.2019.1675458. [Epub ahead of print]

PMID:
31584845
6.

Uptake and safety of hepatitis A vaccination during pregnancy: A Vaccine Safety Datalink study.

Groom HC, Smith N, Irving SA, Koppolu P, Vazquez-Benitez G, Kharbanda EO, Daley MF, Donahue JG, Getahun D, Jackson LA, Klein NP, McCarthy NL, Nordin JD, Panagiotakopoulos L, Naleway AL.

Vaccine. 2019 Oct 16;37(44):6648-6655. doi: 10.1016/j.vaccine.2019.09.043. Epub 2019 Sep 20.

PMID:
31548013
7.

Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15.

Donahue JG, Kieke BA, King JP, Mascola MA, Shimabukuro TT, DeStefano F, Hanson KE, McClure DL, Olaiya O, Glanz JM, Hechter RC, Irving SA, Jackson LA, Klein NP, Naleway AL, Weintraub ES, Belongia EA.

Vaccine. 2019 Oct 16;37(44):6673-6681. doi: 10.1016/j.vaccine.2019.09.035. Epub 2019 Sep 17.

8.

Depletion of Susceptibles Bias in Analyses of Intra-season Waning of Influenza Vaccine Effectiveness.

Ray GT, Lewis N, Klein NP, Daley MF, Lipsitch M, Fireman B.

Clin Infect Dis. 2019 Jul 28. pii: ciz706. doi: 10.1093/cid/ciz706. [Epub ahead of print]

PMID:
31351439
9.

Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention.

Klein NP, Bartlett J, Fireman B, Marks MA, Hansen J, Lewis E, Aukes L, Saddier P.

Vaccine. 2019 Aug 23;37(36):5422-5427. doi: 10.1016/j.vaccine.2019.07.004. Epub 2019 Jul 10.

10.

Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods.

Klein NP, Block SL, Essink B, Barbi S, Smolenov I, Keshavan P.

Vaccine. 2019 Jul 26;37(32):4460-4467. doi: 10.1016/j.vaccine.2019.06.076. Epub 2019 Jul 3.

11.

Associations of Statewide Legislative and Administrative Interventions With Vaccination Status Among Kindergartners in California.

Pingali SC, Delamater PL, Buttenheim AM, Salmon DA, Klein NP, Omer SB.

JAMA. 2019 Jul 2;322(1):49-56. doi: 10.1001/jama.2019.7924.

PMID:
31265099
12.

If Influenza Vaccines Wane Can We Delay Vaccination Without Compromising Coverage?

Klein NP, Fireman B.

Clin Infect Dis. 2019 Jun 29. pii: ciz459. doi: 10.1093/cid/ciz459. [Epub ahead of print] No abstract available.

PMID:
31257408
13.

Incidence of Herpes Zoster Among Children: 2003-2014.

Weinmann S, Naleway AL, Koppolu P, Baxter R, Belongia EA, Hambidge SJ, Irving SA, Jackson ML, Klein NP, Lewin B, Liles E, Marin M, Smith N, Weintraub E, Chun C.

Pediatrics. 2019 Jul;144(1). pii: e20182917. doi: 10.1542/peds.2018-2917. Epub 2019 Jun 10.

PMID:
31182552
14.

Acellular Pertussis Vaccine Effectiveness Over Time.

Zerbo O, Bartlett J, Goddard K, Fireman B, Lewis E, Klein NP.

Pediatrics. 2019 Jul;144(1). pii: e20183466. doi: 10.1542/peds.2018-3466. Epub 2019 Jun 10.

PMID:
31182549
15.

Evaluation of two frailty indices, with practical application in a vaccine clinical trial.

Curran D, Andrew MK, Levin MJ, Turriani E, Matthews S, Fogarty C, Klein NP, Grupping K, Oostvogels L, Schmader KE.

Hum Vaccin Immunother. 2019;15(12):2960-2968. doi: 10.1080/21645515.2019.1622974. Epub 2019 Jun 21.

PMID:
31157595
16.

Elimination of Nonmedical Immunization Exemptions in California and School-Entry Vaccine Status.

Delamater PL, Pingali SC, Buttenheim AM, Salmon DA, Klein NP, Omer SB.

Pediatrics. 2019 Jun;143(6). pii: e20183301. doi: 10.1542/peds.2018-3301. Epub 2019 May 21.

PMID:
31113831
17.

Vaccine safety in HIV-infected adults within the Vaccine Safety Datalink Project.

Hechter RC, Qian L, Tartof SY, Sy LS, Klein NP, Weintraub E, Mercado C, Naleway A, McLean HQ, Jacobsen SJ.

Vaccine. 2019 May 31;37(25):3296-3302. doi: 10.1016/j.vaccine.2019.04.080. Epub 2019 May 4.

18.

Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.

Klein NP, Abu-Elyazeed R, Povey M, Macias Parra M, Diez-Domingo J, Ahonen A, Korhonen T, Tinoco JC, Weiner L, Marshall GS, Silas PE, Sarpong KO, Ramsey KP, Fling JA, Speicher D, Campos M, Munjal I, Peltier C, Vesikari T, Baccarini C, Caplanusi A, Gillard P, Carryn S, Henry O.

J Pediatric Infect Dis Soc. 2019 Mar 8. pii: piz010. doi: 10.1093/jpids/piz010. [Epub ahead of print]

PMID:
30849175
19.

Long term risk of developing type 1 diabetes after HPV vaccination in males and females.

Klein NP, Goddard K, Lewis E, Ross P, Gee J, DeStefano F, Baxter R.

Vaccine. 2019 Mar 28;37(14):1938-1944. doi: 10.1016/j.vaccine.2019.02.051. Epub 2019 Mar 1.

20.

Reply to Skowronski, De Serres, and Orenstein.

Thompson MG, Jackson ML, Regan A, Katz MA, Kwong JC, Ball SW, Simmonds K, Klein NP, Naleway A.

Clin Infect Dis. 2019 Aug 30;69(6):1085-1086. doi: 10.1093/cid/ciz115. No abstract available.

PMID:
30753401
21.

Estimating Vaccine Effectiveness Against Hospitalized Influenza During Pregnancy: Multicountry Protocol for a Retrospective Cohort Study.

Naleway AL, Ball S, Kwong JC, Wyant BE, Katz MA, Regan AK, Russell ML, Klein NP, Chung H, Simmonds KA, Azziz-Baumgartner E, Feldman BS, Levy A, Fell DB, Drews SJ, Garg S, Effler P, Barda N, Irving SA, Shifflett P, Jackson ML, Thompson MG.

JMIR Res Protoc. 2019 Jan 21;8(1):e11333. doi: 10.2196/11333.

22.

Exploring California's new law eliminating personal belief exemptions to childhood vaccines and vaccine decision-making among homeschooling mothers in California.

McDonald P, Limaye RJ, Omer SB, Buttenheim AM, Mohanty S, Klein NP, Salmon DA.

Vaccine. 2019 Jan 29;37(5):742-750. doi: 10.1016/j.vaccine.2018.12.018. Epub 2019 Jan 6.

PMID:
30626531
23.

Comment on "The impact of past vaccination coverage and immunity on pertussis resurgence".

Winter K, Klein NP, Ackley S, Cherry JD.

Sci Transl Med. 2018 Dec 19;10(472). pii: eaau0548. doi: 10.1126/scitranslmed.aau0548.

PMID:
30567926
24.

Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders.

McClure DL, Jacobsen SJ, Klein NP, Naleway AL, Kharbanda EO, Glanz JM, Jackson LA, Weintraub ES, McLean HQ.

Vaccine. 2019 Jan 3;37(1):76-79. doi: 10.1016/j.vaccine.2018.11.038. Epub 2018 Nov 23.

25.
26.

A framework for research on vaccine effectiveness.

Crowcroft NS, Klein NP.

Vaccine. 2018 Nov 19;36(48):7286-7293. doi: 10.1016/j.vaccine.2018.04.016. Epub 2018 Oct 26. Review.

27.

Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age: A Randomized Controlled Clinical Trial.

Robertson CA, Mercer M, Selmani A, Klein NP, Jeanfreau R, Greenberg DP.

Pediatr Infect Dis J. 2019 Mar;38(3):323-328. doi: 10.1097/INF.0000000000002227.

28.

Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010-2016.

Thompson MG, Kwong JC, Regan AK, Katz MA, Drews SJ, Azziz-Baumgartner E, Klein NP, Chung H, Effler PV, Feldman BS, Simmonds K, Wyant BE, Dawood FS, Jackson ML, Fell DB, Levy A, Barda N, Svenson LW, Fink RV, Ball SW, Naleway A; PREVENT Workgroup .

Clin Infect Dis. 2019 Apr 24;68(9):1444-1453. doi: 10.1093/cid/ciy737.

PMID:
30307490
29.

Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.

Thompson AR, Klein NP, Downey HJ, Patterson S, Sundaraiyer V, Watson W, Clarke K, Jansen KU, Sebastian S, Gruber WC, Scott DA, Schmöele-Thoma B.

Hum Vaccin Immunother. 2019;15(2):444-451. doi: 10.1080/21645515.2018.1533777. Epub 2018 Oct 25.

30.

The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial.

Schmader KE, Levin MJ, Grupping K, Matthews S, Butuk D, Chen M, Idrissi ME, Fissette LA, Fogarty C, Hartley P, Klein NP, Nevarez M, Uusinarkaus K, Oostvogels L, Curran D.

J Gerontol A Biol Sci Med Sci. 2019 Jul 12;74(8):1217-1224. doi: 10.1093/gerona/gly218.

32.

Intraseason Waning of Influenza Vaccine Effectiveness.

Ray GT, Lewis N, Klein NP, Daley MF, Wang SV, Kulldorff M, Fireman B.

Clin Infect Dis. 2019 May 2;68(10):1623-1630. doi: 10.1093/cid/ciy770.

PMID:
30204855
33.

Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study.

Groom HC, Irving SA, Koppolu P, Smith N, Vazquez-Benitez G, Kharbanda EO, Daley MF, Donahue JG, Getahun D, Jackson LA, Tse Kawai A, Klein NP, McCarthy NL, Nordin JD, Sukumaran L, Naleway AL.

Vaccine. 2018 Oct 1;36(41):6111-6116. doi: 10.1016/j.vaccine.2018.08.074. Epub 2018 Sep 5.

34.

Factors Affecting Vaccination in Children and Their Siblings After Autism Spectrum Disorder Diagnosis-Reply.

Zerbo O, Klein NP.

JAMA Pediatr. 2018 Oct 1;172(10):985-986. doi: 10.1001/jamapediatrics.2018.2154. No abstract available.

PMID:
30083723
35.

Pneumococcal Conjugate Vaccine Safety in Elderly Adults.

Tseng HF, Sy LS, Qian L, Liu IA, Mercado C, Lewin B, Tartof SY, Nelson J, Jackson LA, Daley MF, Weintraub E, Klein NP, Belongia E, Liles EG, Jacobsen SJ.

Open Forum Infect Dis. 2018 May 2;5(6):ofy100. doi: 10.1093/ofid/ofy100. eCollection 2018 Jun.

36.

Impact of an electronic medical record reminder on hepatitis B vaccine initiation and completion rates among insured adults with diabetes mellitus.

Hechter RC, Qian L, Luo Y, Ling Grant DS, Baxter R, Klein NP, Valdez Nunley K, Aukes L, Hogea C, Krishnarajah G, Patterson BJ, Im TM, Tseng HF.

Vaccine. 2019 Jan 3;37(1):195-201. doi: 10.1016/j.vaccine.2018.06.035. Epub 2018 Jun 27.

PMID:
29958736
37.

Risk of Spontaneous Abortion After Inadvertent Human Papillomavirus Vaccination in Pregnancy.

Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Sheth SS, Zhu J, Naleway AL, Klein NP, Hechter R, Daley MF, Donahue JG, Jackson ML, Kawai AT, Sukumaran L, Nordin JD.

Obstet Gynecol. 2018 Jul;132(1):35-44. doi: 10.1097/AOG.0000000000002694.

38.

Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents.

Jackson ML, Yu O, Nelson JC, Nordin JD, Tartof SY, Klein NP, Donahue JG, Irving SA, Glanz JM, McNeil MM, Jackson LA.

Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):921-925. doi: 10.1002/pds.4569. Epub 2018 Jun 3.

39.

Respiratory Syncytial Virus Hospitalization During Pregnancy in 4 High-income Countries, 2010-2016.

Regan AK, Klein NP, Langley G, Drews SJ, Buchan S, Ball S, Kwong JC, Naleway A, Thompson M, Wyant BE, Levy A, Chung H, Feldman B, Katz MA; PREVENT Group.

Clin Infect Dis. 2018 Nov 28;67(12):1915-1918. doi: 10.1093/cid/ciy439.

PMID:
29800089
40.

Assessing Potential Confounding and Misclassification Bias When Studying the Safety of the Childhood Immunization Schedule.

Daley MF, Shoup JA, Newcomer SR, Jackson ML, Groom HC, Jacobsen SJ, McLean HQ, Klein NP, Weintraub ES, McNeil MM, Glanz JM.

Acad Pediatr. 2018 Sep - Oct;18(7):754-762. doi: 10.1016/j.acap.2018.03.007. Epub 2018 Mar 28.

41.

Vaccination Patterns in Children After Autism Spectrum Disorder Diagnosis and in Their Younger Siblings.

Zerbo O, Modaressi S, Goddard K, Lewis E, Fireman BH, Daley MF, Irving SA, Jackson LA, Donahue JG, Qian L, Getahun D, DeStefano F, McNeil MM, Klein NP.

JAMA Pediatr. 2018 May 1;172(5):469-475. doi: 10.1001/jamapediatrics.2018.0082.

42.

Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.

Klein NP, Habanec T, Kosina P, Shah NR, Kolhe D, Miller JM, Hezareh M, Van der Wielen M.

Vaccine. 2018 Apr 19;36(17):2356-2363. doi: 10.1016/j.vaccine.2018.02.085. Epub 2018 Mar 22.

43.

Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children.

Hansen J, Zhang L, Eaton A, Baxter R, Robertson CA, Decker MD, Greenberg DP, Bassily E, Klein NP.

Vaccine. 2018 Apr 12;36(16):2133-2138. doi: 10.1016/j.vaccine.2018.02.107. Epub 2018 Mar 14.

44.

Infant Hospitalizations and Mortality After Maternal Vaccination.

Sukumaran L, McCarthy NL, Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Jackson L, Klein NP, Naleway AL, McClure DL, Hechter RC, Kawai AT, Glanz JM, Weintraub ES.

Pediatrics. 2018 Mar;141(3). pii: e20173310. doi: 10.1542/peds.2017-3310. Epub 2018 Feb 20.

45.

Meningococcal conjugate vaccine safety surveillance in the Vaccine Safety Datalink using a tree-temporal scan data mining method.

Li R, Weintraub E, McNeil MM, Kulldorff M, Lewis EM, Nelson J, Xu S, Qian L, Klein NP, Destefano F.

Pharmacoepidemiol Drug Saf. 2018 Apr;27(4):391-397. doi: 10.1002/pds.4397. Epub 2018 Feb 15.

PMID:
29446176
46.

Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study.

Baxter R, Bartlett J, Fireman B, Marks M, Hansen J, Lewis E, Aukes L, Chen Y, Klein NP, Saddier P.

Am J Epidemiol. 2018 Jan 1;187(1):161-169. doi: 10.1093/aje/kwx245.

47.

Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults.

Storms AD, Chen J, Jackson LA, Nordin JD, Naleway AL, Glanz JM, Jacobsen SJ, Weintraub ES, Klein NP, Gargiullo PM, Fry AM.

BMC Pulm Med. 2017 Dec 16;17(1):208. doi: 10.1186/s12890-017-0552-x.

48.

Respiratory distress in the neonate: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data.

Sweet LR, Keech C, Klein NP, Marshall HS, Tagbo BN, Quine D, Kaur P, Tikhonov I, Nisar MI, Kochhar S, Muñoz FM; Brighton Collaboration Respiratory Distress in the Neonate Working Group.

Vaccine. 2017 Dec 4;35(48 Pt A):6506-6517. doi: 10.1016/j.vaccine.2017.01.046. No abstract available.

49.

Congenital microcephaly: Case definition & guidelines for data collection, analysis, and presentation of safety data after maternal immunisation.

DeSilva M, Munoz FM, Sell E, Marshall H, Tse Kawai A, Kachikis A, Heath P, Klein NP, Oleske JM, Jehan F, Spiegel H, Nesin M, Tagbo BN, Shrestha A, Cutland CL, Eckert LO, Kochhar S, Bardají A; Brighton Collaboration Congenital Microcephaly Working Group.

Vaccine. 2017 Dec 4;35(48 Pt A):6472-6482. doi: 10.1016/j.vaccine.2017.01.044. No abstract available.

50.

The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study.

Daley MF, Clarke CL, Glanz JM, Xu S, Hambidge SJ, Donahue JG, Nordin JD, Klein NP, Jacobsen SJ, Naleway AL, Jackson ML, Lee G, Duffy J, Weintraub E.

Pharmacoepidemiol Drug Saf. 2018 Jan;27(1):59-68. doi: 10.1002/pds.4349. Epub 2017 Nov 17.

Supplemental Content

Loading ...
Support Center